Business
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
TORONTO, ONTARIO - February 24, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are...
About this update from Helix Biopharma Corp.
[{"type":"image","caption":"","headline":"Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London","size":{"original":{"width":140,"height":50,"url":"https://media.zenfs.com/en/newsmediawire_165/54ac0a9149598ff21c37ef7ad9949aa6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZwaAVzOd9M1EvRYEDXyi9g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc1O2NmPXdlYnA-/https://media.zenfs.com/en/newsmediawire_165/54ac0a9149598ff21c37ef7ad9949aa6","width":140,"height":50}}},{"type":"text","content":"TORONTO, ONTARIO - February 24, 2026 (NEWMEDIAWIRE) - Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, is pleased to announce that the Company presented new data yesterday on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference, held in London, United Kingdom.","length":525,"tagName":"p"},{"type":"text","content":"The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies", was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference's opening day. Dr. Davis was selected to present as part of the conference's Seminar Day program, which brings together leading ADC experts to address key challenges and opportunities in next-generation conjugate design, safety, combination strategies, and regulatory development. His participation underscores Helix's growing leadership in the development of innovative ADC technologies. The World ADC London conference continues over the following two days with a comprehensive scientific program covering advances in ADC discovery, development, and clinical translation.","length":818,"tagName":"p"},{"type":"text","content":"The presentation highlighted CEACAM6 as a highly attractive therapeutic target, based on its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis also presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibod...